Veritas In Silico Inc. (JP:130A) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Veritas In Silico Inc. has partnered with Liverpool ChiroChem to develop mRNA-targeted small molecule drugs, aiming to create innovative therapeutics for various diseases. This strategic collaboration combines both companies’ platforms to potentially generate groundbreaking drug candidates. The agreement marks a significant step in Veritas In Silico’s growth strategy, although no immediate revenue is expected from this contract.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Will Shari Redstone’s Relationship With Trump Save Paramount (NASDAQ:PARA) Merger?
- Ford (NYSE:F) Offers Free Cars to Trump Inauguration
- Rest Easy, Intel (NASDAQ:INTC): Broadcom Is Not Coming For You
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Price%2FEarnings%20%26%20PEG%20Ratios%20%7C%20Nasdaq&_biz_n=6&rnd=884225&cdn_o=a&_biz_z=1743045821276)
%20News%20Headlines%20%7C%20Nasdaq&_biz_n=9&rnd=418309&cdn_o=a&_biz_z=1743045821519)
%20News%20Headlines%20%7C%20Nasdaq&_biz_n=10&rnd=498459&cdn_o=a&_biz_z=1743045821519)
